Literature DB >> 32115333

Endoscopic assisted breast conserving surgery for breast cancer: Clinical outcome, learning curve, and patient reported aesthetic results from preliminary 100 procedures.

Hung-Wen Lai1, Chi Wei Mok2, Yun-Ting Chang3, Dar-Ren Chen4, Shou-Jen Kuo4, Shou-Tung Chen5.   

Abstract

BACKGROUND: Endoscopic assisted breast surgery was associated with small and inconspicuous scar and endoscopic assisted breast conserving surgery (E-BCS) for breast cancer was increasingly performed as well. The clinical outcomes, learning curve analysis and patient reported cosmetic result of E-BCS for breast cancer were reported along with a review of the current literature.
METHODS: A retrospective study analyzing the outcomes of E-BCS for breast cancer patients through an endoscopic breast surgery database in a single institution from June 2009 to May 2019 was performed and a literature review through Pubmed and Medline was conducted as well.
RESULTS: 100 consecutive breast cancer patients who underwent E-BCS were analyzed. The mean age of patients was 52.5 years old. Furthermore, the mean pathologic tumor size was 1.6 cm and majority of patients had early stage (13% stage 0, 56% stage I, and 30% stage II) breast cancer. The mean operation time of E-BCS in the current study was 133 ± 50 min and in learning curve analysis, after accumulation of 15 consecutive cases the operation time significantly decreased. The morbidities of E-BCS were minor and most of them were skin flap related. The margin involvement rate was 4%. About 98% of patients surveyed were satisfied with the incision length, location and scar appearance of E-BCS whereas all of them were satisfied with E-BCS in general. With a mean follow-up of 29.2 ± 24.4 months, 3% of patients developed locoregional recurrences, 3% had distant metastasis and there were 2 mortalities observed.
CONCLUSION: In our preliminary experience, E-BCS is a promising surgical technique for selected early breast cancer patients with low morbidity, acceptable oncological outcomes and high patient satisfaction.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cosmesis; Endoscopic breast conserving surgery (E-BCS); Oncological outcomes; Video-assisted breast surgery

Year:  2020        PMID: 32115333     DOI: 10.1016/j.ejso.2020.02.020

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Oncologic Outcome of Endoscopic Assisted Breast Surgery Compared with Conventional Approach in Breast Cancer: An Analysis of 3426 Primary Operable Breast Cancer Patients from Single Institute with and Without Propensity Score Matching.

Authors:  Hung-Wen Lai; Shou-Tung Chen; Chiung-Ying Liao; Chi Wei Mok; Ying-Jen Lin; Dar-Ren Chen; Shou-Jen Kuo
Journal:  Ann Surg Oncol       Date:  2021-05-11       Impact factor: 5.344

2.  EphA2 as a new target for breast cancer and its potential clinical application.

Authors:  Lingzhi Zhou; Xuejing Lu; Bensi Zhang; Yaqi Shi; Zhuang Li
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

3.  Minimal Access (Endoscopic and Robotic) Breast Surgery in the Surgical Treatment of Early Breast Cancer-Trend and Clinical Outcome From a Single-Surgeon Experience Over 10 Years.

Authors:  Hung-Wen Lai; Shou-Tung Chen; Ying-Jen Lin; Shih-Lung Lin; Ching-Min Lin; Dar-Ren Chen; Shou-Jen Kuo
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

4.  Efficacy of digital breast tomosynthesis combined with magnetic resonance imaging in the diagnosis of early breast cancer.

Authors:  Yun Ren; Jiao Zhang; Jin-Dan Zhang; Jian-Zhong Xu
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

5.  Comparing outcomes of single-port insufflation endoscopic breast-conserving surgery and conventional open approach for breast cancer.

Authors:  Fang Xie; Zi-Han Wang; Shan-Shan Wu; Tian-Ran Gang; Guo-Xuan Gao; Xiang Qu; Zhong-Tao Zhang
Journal:  World J Surg Oncol       Date:  2022-10-06       Impact factor: 3.253

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.